Vertex Pharmaceuticals today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for PrALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), a new ...
"This agreement reflects a shared commitment to improve access to innovative cystic fibrosis medicines," said Michael Siauw, Executive Country Manager, Vertex Pharmaceuticals (Canada). "We would like ...
TORONTO, July 6, 2026 /CNW/ - Vertex Pharmaceuticals today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results